Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Connect Biopharma HoldingsCNTB -2.19%10 Equity-to-Asset is 0.62 as of Jun. 2026, which is 30% below its 10-year median of 0.88. GuruFocus rates CNTB with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 1,414 Biotechnology companies, Connect Biopharma Holdings ranks worse than 56.86% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Connect Biopharma Holdings Equity-to-Asset Related Terms
Connect Biopharma Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNTB vs MIST, HURA, UNCY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Connect Biopharma Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Connect Biopharma Holdings Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Connect Biopharma Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Connect Biopharma Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Connect Biopharma Holdings (CNTB) has a Equity-to-Asset of 0.62 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Connect Biopharma Holdings and its competitors. This is 30% below median its historical median of 0.88. According to the industry distribution chart, Connect Biopharma Holdings ranks #804 out of 1414 companies in the Biotechnology industry, placing it in the top 56.9%.
Is Connect Biopharma Holdings' Equity-to-Asset too high?
Connect Biopharma Holdings' current Equity-to-Asset of 0.62 is 30% below median its 10-year median of 0.88. The Biotechnology industry median Equity-to-Asset is 0.69. Connect Biopharma Holdings' value of 0.62 is 10.1% below this industry median. Based on the distribution chart, Connect Biopharma Holdings ranks #804 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Connect Biopharma Holdings has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' Equity-to-Asset compare to MIST and HURA?
According to the Biotechnology industry distribution chart, Connect Biopharma Holdings ranks #804 out of 1414 companies for Equity-to-Asset. This places Connect Biopharma Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Connect Biopharma Holdings' value of 0.62 is 10.1% below this benchmark. While the company's 10-year median is 0.88 vs. the industry median of 0.69, Connect Biopharma Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Connect Biopharma Holdings's current Equity-to-Asset of 0.62 is 10.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Connect Biopharma Holdings and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Connect Biopharma Holdings's current Equity-to-Asset is 0.62, which is 30% below median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current Equity-to-Asset of 0.62. The current Equity-to-Asset is 0.62, which is 30% below median its 10-year median of 0.88 and 10.1% below the Biotechnology industry median of 0.69. Connect Biopharma Holdings' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current Equity-to-Asset is 0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
10GF Score
Get the complete analysis for CNTB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTB has been successfully added to your 
